ACUTE INTERMITTENT PORPHOZYM

急性间歇性卟啉病

基本信息

项目摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Acute Intermittemt Porphozym is caused by an inherited defect of the enzyme porphobilinogen deaminase (PBGD), the third enzyme in the biosynthetic pathway leading to heme. The new treatment, which has been made in a biological laboratory by modern methods of molecular biology, is a preparation of this enzyme, rhPBGD, Porphozym¿. The purpose of the trial is to compare the efficacy and safety of Porphozym¿ with that of placebo as a treatment of AIP in subjects with acute attacks. The placebo is an inactive material identical in appearance to the drug undergoing testing. The Danish/Swedish company, HemeBiotech A/S, will supply both Porphozym¿ and placebo. After coming to the hospital with an acute attack, and signing the study consent form, you will be given treatment with either Porphozym¿ or placebo. You will be assigned to a treatment based on a pre-determined order decided at random (like flipping a coin). Therefore you will have a 50% chance of receiving the new treatment. Neither your doctor nor you will know which treatment you will receive. Treatment will be given into a blood vessel (a vein) over a period of 48 hours. You will be followed until you are discharged from the hospital. 14 days and 28 days after end of treatment you will come to the outpatient clinic for a follow-up visit. If you do not experience a new attack before the last of these visits, you will be followed until your next attack or for 6 months, whichever comes first.
该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者(PI)可能从另一个NIH来源获得主要资金,因此可以在其他CRISP条目中表示。所列机构为中心,不一定是研究者所在机构。急性间歇性卟啉酶是由胆色素原脱氨酶(PBGD)的遗传缺陷引起的,PBGD是导致血红素的生物合成途径中的第三种酶。这种新的治疗方法是在生物实验室中通过现代分子生物学方法进行的,是这种酶rhPBGD,Porphozym?的制备。该试验的目的是比较Porphozym?与安慰剂治疗急性发作受试者AIP的疗效和安全性。安慰剂是一种外观与试验药物相同的非活性物质。丹麦/瑞典公司HemeBiotech A/S将提供Porphozym和安慰剂。在急性发作来到医院并签署研究知情同意书后,您将接受Porphozym?或安慰剂治疗。您将被随机分配到一个预先确定的治疗顺序(如抛硬币)。因此,您将有50%的机会接受新的治疗。你和你的医生都不知道你会接受哪种治疗。将在48小时内对血管(静脉)进行治疗。您将被随访至出院。治疗结束后14天和28天,您将前往门诊进行随访。如果您在最后一次访视前未发生新的发作,则将对您进行随访,直至您下次发作或随访6个月,以先发生者为准。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

HERBERT L BONKOVSKY其他文献

HERBERT L BONKOVSKY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('HERBERT L BONKOVSKY', 18)}}的其他基金

Effect of Heme on mRNA and miRNA Profiles
血红素对 mRNA 和 miRNA 谱的影响
  • 批准号:
    8432952
  • 财政年份:
    2013
  • 资助金额:
    $ 0.43万
  • 项目类别:
Effect of Heme on mRNA and miRNA Profile
血红素对 mRNA 和 miRNA 谱的影响
  • 批准号:
    9096937
  • 财政年份:
    2013
  • 资助金额:
    $ 0.43万
  • 项目类别:
CLINICAL TRIAL: HALT-C TRIAL
临床试验:HALT-C 试验
  • 批准号:
    7719096
  • 财政年份:
    2008
  • 资助金额:
    $ 0.43万
  • 项目类别:
DRUG- AND CAM-INDUCED LIVER INJURY
药物和凸轮引起的肝损伤
  • 批准号:
    7607623
  • 财政年份:
    2007
  • 资助金额:
    $ 0.43万
  • 项目类别:
ILIAD
伊利亚德
  • 批准号:
    7607620
  • 财政年份:
    2007
  • 资助金额:
    $ 0.43万
  • 项目类别:
HALT-C TRIAL
HALT-C 试验
  • 批准号:
    7607590
  • 财政年份:
    2007
  • 资助金额:
    $ 0.43万
  • 项目类别:
DRUG- AND CAM-INDUCED LIVER INJURY
药物和凸轮引起的肝损伤
  • 批准号:
    7377361
  • 财政年份:
    2006
  • 资助金额:
    $ 0.43万
  • 项目类别:
HALT-C TRIAL
HALT-C 试验
  • 批准号:
    7377318
  • 财政年份:
    2006
  • 资助金额:
    $ 0.43万
  • 项目类别:
IRON
  • 批准号:
    7377330
  • 财政年份:
    2006
  • 资助金额:
    $ 0.43万
  • 项目类别:
DISCOVERY AND ASSESSMENT OF GENETIC AND ENVIRONMENT
遗传和环境的发现和评估
  • 批准号:
    7377328
  • 财政年份:
    2006
  • 资助金额:
    $ 0.43万
  • 项目类别:

相似国自然基金

Toward a general theory of intermittent aeolian and fluvial nonsuspended sediment transport
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    55 万元
  • 项目类别:

相似海外基金

CAREER: Elastic Intermittent Computation Enabling Batteryless Edge Intelligence
职业:弹性间歇计算实现无电池边缘智能
  • 批准号:
    2339193
  • 财政年份:
    2024
  • 资助金额:
    $ 0.43万
  • 项目类别:
    Continuing Grant
Rights of Nature: The Legal Geographies and Political Ecologies of Intermittent Rivers in Sri Lanka
自然权利:斯里兰卡间歇性河流的法律地理和政治生态
  • 批准号:
    2878902
  • 财政年份:
    2023
  • 资助金额:
    $ 0.43万
  • 项目类别:
    Studentship
Intermittent Fasting using a Fasting-Mimetic Diet to Improve Prostate Cancer Control and Metabolic Outcomes
使用模拟禁食饮食进行间歇性禁食以改善前列腺癌控制和代谢结果
  • 批准号:
    10639416
  • 财政年份:
    2023
  • 资助金额:
    $ 0.43万
  • 项目类别:
A Randomized Clinical Trial of Continuous vs. Intermittent Infusion Vancomycin: Effects on Measured GFR and Kidney Injury Biomarkers
连续与间歇输注万古霉素的随机临床试验:对测量的 GFR 和肾损伤生物标志物的影响
  • 批准号:
    10647236
  • 财政年份:
    2023
  • 资助金额:
    $ 0.43万
  • 项目类别:
Intermittent Hypoxia Initiated Motor Plasticity in Individuals with Multiple Sclerosis
间歇性缺氧引发多发性硬化症患者的运动可塑性
  • 批准号:
    10593412
  • 财政年份:
    2023
  • 资助金额:
    $ 0.43万
  • 项目类别:
CNS-mediated fever after Adolescent Intermittent Ethanol
青少年间歇性饮酒后中枢神经系统介导的发热
  • 批准号:
    10607154
  • 财政年份:
    2023
  • 资助金额:
    $ 0.43万
  • 项目类别:
Collaborative Research: SaTC: CORE: Medium: Security and Robustness for Intermittent Computing Using Cross-Layer Post-CMOS Approaches
协作研究:SaTC:CORE:中:使用跨层后 CMOS 方法的间歇计算的安全性和鲁棒性
  • 批准号:
    2303115
  • 财政年份:
    2023
  • 资助金额:
    $ 0.43万
  • 项目类别:
    Continuing Grant
Acute intermittent hypoxia as a novel cardio-therapeutic for spinal cord injury
急性间歇性缺氧作为脊髓损伤的新型心脏治疗方法
  • 批准号:
    478667
  • 财政年份:
    2023
  • 资助金额:
    $ 0.43万
  • 项目类别:
    Operating Grants
The mechanism of non-dipper blood pressure induced by intermittent hypoxia during sleep
睡眠间歇性缺氧引起非杓型血压的机制
  • 批准号:
    23K06336
  • 财政年份:
    2023
  • 资助金额:
    $ 0.43万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Apnea, sex and FMO: Are flavin-containing monooxygenases the new anti-ox that prevent metabolic disorders under intermittent hypoxia?
呼吸暂停、性和 FMO:含黄素单加氧酶是预防间歇性缺氧下代谢紊乱的新型抗氧化酶吗?
  • 批准号:
    487678
  • 财政年份:
    2023
  • 资助金额:
    $ 0.43万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了